ClinicalTrials.gg
RecruitingNCT07811999Updated Oct 13, 2026

Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections

A Phase 1 interventional study of Romosozumab in Healthy Participants, sponsored by Amgen. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 13, 2026Now RecruitingFirst sites in United States and United Kingdom+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of this trial is to evaluate the relative bioavailability of romosozumab administered as a single 2.34 mL subcutaneous (SC) injection from a prefilled syringe (PFS) or 2 x 1.17 mL SC injections from PFS in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • AMG 785
  • Healthy Participants
  • Romosozumab
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults, male or female, 18 to 60 years of age.
  • Able and willing to provide written before any study procedures.
  • Body weight between 45.0 kg and 95.0 kg (inclusive).
  • Women must not be able to become pregnant (for example, or permanently sterile, as defined by the protocol).
  • Men who can father a child must agree to use the required during the study and for 3 months after the study drug dose.
  • Willing and able to take daily calcium (500 to 2,000 mg elemental calcium) and vitamin D (at least 400 IU) supplements from Day 1 through the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Any medical condition or abnormal finding that, in the opinion of the study doctor, could make participation unsafe or interfere with the study or its results.
  • Clinically significant abnormalities on medical history, physical examination, vital signs, (ECG), or laboratory tests, including suspected Gilbert syndrome.
  • History or current signs or symptoms of significant cardiovascular disease, including heart attack, heart failure, congenital heart disease, cardiomyopathy, valve disease, angina, coronary revascularization, stroke, , or peripheral revascularization.
  • Clinically significant abnormal heart rhythm or conduction disorder, including clinically significant ECG abnormalities.
  • corrected for heart rate (QTcF) greater than 450 milliseconds for men or greater than 470 milliseconds for women, or a history of long QT syndrome.
  • Second- or third-degree atrioventricular (AV) block.
  • Systolic blood pressure greater than 140 millimeters of mercury (mmHg) or less than 90 mmHg, diastolic blood pressure greater than 90 mmHg or less than 50 mmHg, or pulse rate greater than 100 beats per minute or less than 40 beats per minute at screening or check-in.
  • Deep vein thrombosis or pulmonary embolism within 3 months before screening.
  • History of osteoporosis, vertebral fracture, or a fragility fracture of the wrist, upper arm, hip, or pelvis after 50 years of age.
  • History of metabolic bone disease, including conditions such as Paget disease, osteomalacia, osteogenesis imperfecta, osteopetrosis, sclerosteosis, ankylosing spondylitis, rheumatoid arthritis, Cushing disease, hyperprolactinemia, or malabsorption syndrome.
  • History of osteonecrosis of the jaw.
  • Bone fracture within 6 months before screening.
  • Vitamin D level below 20 nanograms per milliliter (ng/mL) at screening (participants may be treated and retested before enrollment).
  • Current hyperparathyroidism or hypoparathyroidism.
  • Kidney function below study requirements (estimated less than 60 mL/min/1.73 m\^2).
  • Low or high blood calcium levels that do not meet study requirements.
  • Liver blood test results ( [ALT] or aspartate aminotransferase [AST]) above the normal range.
  • History of hyperthyroidism or hypothyroidism unless on stable treatment for at least 6 months with normal thyroid function tests.
  • History of hearing loss caused by excessive bone growth compressing the eighth cranial nerve.
  • Positive test for (HIV).
  • Active or infection.
  • Cancer within the past 5 years, except non-melanoma skin cancer or cervical or breast ductal carcinoma in situ.
  • History of solid organ or bone marrow transplantation.
  • History of allergy or to romosozumab, its ingredients, other biologic medicines, or medicines derived from mammalian cells.
  • Previous use of medications affecting bone metabolism that are not allowed by the protocol, including:
  • Any intravenous or oral bisphosphonate.
  • Fluoride for osteoporosis within 24 months before screening.
  • Denosumab or cathepsin K inhibitors within 18 months before screening.
  • Parathyroid hormone or strontium within 12 months before screening.
  • Calcitonin, selective estrogen receptor modulators, or tibolone within 3 months before screening.
  • Systemic (5 mg or more prednisone equivalent daily for more than 10 days) within 3 months before screening.
  • Use of prescription or over-the-counter medications within 30 days or 5 half-lives (whichever is longer) before check-in, unless approved by the study doctor. Acetaminophen up to 2 g/day is permitted. Stable hormone replacement therapy is allowed if unchanged for at least 3 months before dosing and throughout the study.
  • Use of herbal medicines, vitamins (other than study-required calcium and vitamin D), or dietary supplements within 30 days before enrollment unless approved by the study doctor.
  • Currently participating in another clinical study, receiving another treatment, or participation in another investigational drug or device study within the previous 90 days or 5 half-lives (whichever is longer).
  • Previous participation in this study or previous exposure to a sclerostin antibody.
  • History of alcohol abuse or regular alcohol intake greater than 14 units per week within the year before check-in.
  • Alcohol use within 48 hours before check-in or unwillingness to comply with study alcohol restrictions.
  • Positive alcohol test at check-in.
  • Positive drug screen for illicit drugs, including cannabis, at screening or check-in.
  • History of illicit drug use within 6 months before screening.
  • Unwilling to avoid illicit drug use, including cannabis, throughout the study.
  • Smoking more than 10 cigarettes per day or equivalent nicotine use within 1 month before check-in, or unwillingness to comply with study tobacco restrictions.
  • Consumption of foods or drinks containing poppy seeds within 7 days before check-in.
  • Positive pregnancy test at screening or check-in.
  • Pregnant, breastfeeding, or planning to breastfeed during the study or within 3 months after receiving the study drug.
  • Receipt of blood products within 2 months before check-in.
  • Blood donation within 3 months before screening, plasma donation within 2 weeks before screening, or donation within 6 weeks before screening.
  • Poor veins that would make repeated blood sampling difficult.
  • Any other reason that, in the opinion of the study doctor, would make participation unsafe or inappropriate.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
308 participants (estimated)

Study arms

  • Experimental
    Romosozumab Test Arm

    Participants will receive a single SC injection of romosozumab (test) administered using a PFS.

    Drug: Romosozumab

  • Active comparator
    Romosozumab Reference Arm

    Participants will receive two SC injections of romosozumab (reference) administered using a PFS.

    Drug: Romosozumab

Interventions

  • Romosozumab will be administered via SC injection using a PFS.

    Also known as: AMG 785, Evenity®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of romosozumab

    Time frame: Up to Day 85

  2. Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) of romosozumab

    Time frame: Up to Day 85

  3. Maximum Observed Serum Concentration (Cmax) of romosozumab

    Time frame: Up to Day 85

Secondary outcomes

  1. Number of Participants Who Experienced Treatment-Emergent Adverse Events and Serious Adverse Events

    Time frame: Up to Day 85

  2. Number of Participants Who Developed Anti-romosozumab Antibodies

    Time frame: Up to Day 85

07

Study locations

2 of 2 sites recruiting
  • QPS Miami
    Miami, Florida 33143, United States
    Recruiting
  • Fortrea Clinical Research Unit Limited - Leeds
    Leeds, LDS LS11 9EH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Sep 10, 2026
StartActual
Sep 22, 2026
Primary completionEst.
Jan 14, 2027
CompletionEst.
Jan 14, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
2 sites added — first sites in United States and United Kingdom
Show 2 added (1 United States, 1 United Kingdom)
  • QPS Miami · Miami, United States
  • Fortrea Clinical Research Unit Limited - Leeds · Leeds, United Kingdom
across 2 updates, Oct 5, 2026 – Oct 13, 2026
Show all 2 updates
  1. Oct 13, 2026
    1 site added — first site in United Kingdom
    Show site
    • Fortrea Clinical Research Unit Limited - Leeds · Leeds, United Kingdom
    + 2 other changes: verification date and date precision
  2. Oct 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • QPS Miami · Miami, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07811999
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Sep 22, 2026
Primary completion
Jan 14, 2027 (estimated)
Completion
Jan 14, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion